<DOC>
	<DOC>NCT01450618</DOC>
	<brief_summary>This study will be a retrospective observational study assessing identifiable tolerability problems in terms of their comparative incidence among Human Immunodeficiency Virus (HIV) patients treated with cART regimens including one of four different protease inhibitors [Atazanavir sulfate (ATV), Darunavir (DRV), Fosamprenavir (FPV), or Lopinavir (LPV)] and the impact of these identifiable tolerability problems on PI persistence, healthcare utilization, and healthcare costs.</brief_summary>
	<brief_title>Comparative Tolerability of Protease Inhibitors</brief_title>
	<detailed_description />
	<mesh_term>Protease Inhibitors</mesh_term>
	<mesh_term>Fosamprenavir</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<criteria>Initiated treatment with a Protease inhibitor (PI)based Combination antiretroviral therapy (cART) regimen Between 1864 years of age on the index date At least 6 months of continuous enrollment and pharmacy benefits prior to the index date At least 6 months of continuous enrollment and pharmacy benefits following the index date At least 1 medical claim during the 6month followup period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>